A PharmaNet Oncology Publication

Editorial Staff Anne-Marie Hess Vice President, Marketing & Corporate Communications 609 951 6842 Diane Mitchell Associate Director, Corporate Communications 609 580 8215 Rick Nelson Vice President, Clinical Research 609 951 6633 Miranda Sarwer Sr. Director, Business Development 609-951-6840 Ann ...


Radiation Oncology Accreditation Program Requirements

This document is copyright protected by the American College of Radiology. Any attempt to reproduce, copy, modify, alter or otherwise change or use this document without the express written permission of the American College of Radiology is prohibited.


The Ohio State University

37 Revised 5/21/10 The Ohio State University Department of Orthopaedics Orthopaedic Residency Program Musculoskeletal Oncology Service Information Joel Mayerson, MD Director, Division of Musculoskeletal Oncology Pager: 614- 346-1718 [email protected] Office: 4100 Cramblett Hall Tom ...


2011 Oncology Nursing Certification - OCN

2011 Oncology Nursing Certification Test Bulletin . OCN ® • CPHON ® • CBCN ® • AOCNP ® • AOCNS ® OCN ® , CPHON ® & CBCN


for Chemotherapy-Induced and Febrile Neutropenia

Oncology Nursing Forum • Vol. 37, No. 6, November 2010 765 C. hemotherapy-induced neutropenia (CIN) is a serious toxicity of cancer treatment.


What is an Oncology Dietitian?

What is an Oncology Dietitian? Research has shown that nutrition is an important part of cancer treatment. Adequate nutrition can help ensure maintenance of strength and energy and help promote healing.



Oncology . Payment Policy . Originated 03/2007, Revised 01/2012 1 of 6 Tufts Health Plan — Oncology Payment Policy


The Role of the Oncology Registered Nurse In Outpatient ...

The Role of the Oncology Registered Nurse In Outpatient Medical Oncology AAcckknnoowwlleeddggeemmeennttss “The Role of the Oncology Registered Nurse in Outpatient Medical Oncology” would



ONCOLOGY                       In the oncology space, MCS has represented clients ranging from multinational corporations to advocacy groups.


Clavis Pharma and Clovis Oncology Sign $380 Million ...

Clavis Pharma and Clovis Oncology Sign $380 Million Partnership for the Development and Commercialisation of Anti-Cancer Agent CP-4126 ∞ CP-4126 is a novel, lipid-conjugated form of gemcitabine designed by Clavis Pharma to improve treatment outcomes in patients with pancreatic and other solid ...


Other sites you could try:

Find videos related to Oncology